Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Status:
Recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
This study was designed to investigate whether the oral proteasome inhibitor ixazomib
combined with low-dose lenalidomide(10mg) as a maintenance regimen could improve the outcome
and prognosis of patients with high-risk multiple myeloma after induction and consolidation
of VRD-based regimen.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Dongyang People's Hospital First Affiliated Hospital of Jiaxing University Huizhou Municipal Central Hospital Lishui Country People's Hospital Shangyu People's Hospital Shaoxing People's Hospital Shaoxing Second Hospital